CD38 and Miyoshi myopathy: It is considered incurable[15] and accounts for ≈1.8% of new cancer cases and 2.1% of cancer‐related deaths in the United States.[16] Frequently used MM treatments, daratumumab (a human IgG1κ mAb targeting CD38, CAS number: 945721‐28‐8),[17] and lenalidomide (an immune regulator), either alone or in combination,[18] show limitations.